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The Philadelphia chromosome (Phi), present in >195% 
of chronic myelogenous leukemia (CML) patients, is a 
well-characterized translocation that results in a unique 
chimeric gene product (BCR/ABL) with transforming 
capability. Molecular methods utilizing the polymerase 
chain reaction (PCR) to detect BCR/ABL mRNA tran- 
scripts has been useful for detecting minimal residual 
disease (MRD) after treatment, as well as for establish- 
ing the diagnosis of  CML. Amplification-based assays 
for the BCR/ABL transcript, however, have shown vari- 
able reproducibility and sensitivity. This variability may 
be largely due to technical differences and insufficient 
controls. In this report, we describe the development of 
a highly controlled, reproducible, and sensitive PCR as- 
say to detect Phi that is well suited to clinical and re- 
search applications. A validation study of 82 samples 
was performed consisting of 25 dilutions ofK562 cells 
(Phl +) into normal cultured B cells, 26 pre- and post- 
transplant peripheral blood samples from CML pa- 
tients, 16 peripheral blood samples for diagnosis of 
CML, and 15 peripheral blood samples from healthy 
individuals. RNA isolated from 3 to 5 million leukocytes 
was reverse transcribed (RT) and amplified by nested 
primer PCR. The products were characterized using 
agarose gel electrophoresis. Approximately 1000 Phi- 
positive cells admixed with 106 normal cells were de- 
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tectable after one round of amplification. In 60% of 
assays where one Phi-positive cell was admixed with 
106 normal cells, a BCR/ABL product was detectable 
after nested primer PCR. Specific measures to ensure 
accurate results in routine testing included (a) assessing 
RNA integrity and adequate eDNA preparation by de- 
tection of the constitutively expressed ABL mRNA, (b) 
monitoring sensitivity with the addition and detection of 
K562 RNA mixed with RNA from unknown samples 
(failure to detect the "spiked" K562 RNA indicates the 
presence of inhibitors or ribonucleases within the un- 
known RNA sample), (c) detection of nucleic acid con- 
taminants by using negative controls in every assay, 
and (d) duplicate analysis of all samples and controls. 
Internally, this assay was 100% reproducible. Our re- 
sults verify that nested primer RT-PCR is a fast, sensi- 
tive alternative to cytogenetic or Southern blot analysis 
for monitoring MRD after treatment and for diagnosis 
of CML. In addition, the highly controlled detection 
scheme presented here can be used as a general model 
for the development of other amplification-based detec- 
tion assays. 
Introduction 
The Philadelphia ch romosome  (Phi) is a t runcated 
derivative of  ch romosome  22 that arises through a 
reciprocal translocation involving the long arms of  
ch romosomes  9 and 22 and is observed  in - 9 5 %  of  
chronic myelogenous  leukemia (CML) patients.  A 
chimeric gene, BCR/ABL,  is genera ted through 
the translocation of the ups t ream region of  the 
BCR gene (located on ch romosome  22) to the A B L  
gene (located on ch romosome  9). Breakpoints  on 
ch romosome  9 occur  within a wide region, in >200 
kilobases (kb), extending f rom exon 2 of A B L  to a 
distance 5' of  the entire gene. Breakpoin t s  on 
ch romosome  22 occur  intronically clustered near  
the middle the BCR gene, within a f ive-exon re- 
gion designated the major  breakpoint  cluster  re- 
gion (M-BCR). Although the D N A  breakpoin ts  
within the BCR and A B L  genes are variable,  R N A  
splicing results in precise exon joining. In C M L  
cells, this hybrid m R N A  consists  of  BCR exon 
2/ABL exon 2 (B2A2) and/or BCR exon 3/ABL 
exon 2 (B3A2) fusions. This 8.5-kb transcript  is 
translated into a 210-kD protein (P210) with al- 
tered tyrosine kinase activity,  which is implicated 
in the progression of  C M L  [1]. 
Selective amplification of  the chimeric  BCR/  
ABL  oncogene  m R N A  transcr ipt  using reverse  
transcription and the po lymerase  chain reaction 
(RT-PCR) enables faster  and significantly more 
sensitive detection of  Phi -pos i t ive  cells than cyto- 
genetic analysis or Southern blotting [2]. These  
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alternative techniques require that Phi-positive 
cells comprise at least 1% of the leukocyte popu- 
lation for detection. RT-PCR Detection of Phi has 
utility as a means of monitoring patients after bone 
marrow transplant (BMT) for minimal residual dis- 
ease (MRD). Recent studies have now demon- 
strated that PCR detection of Phi-positive cells is 
valuable in predicting disease progression for 
CML patients in apparent clinical remission after 
BMT [3]. These studies have shown that CML 
patients persistently positive for the BCR/ABL 
mRNA by RT-PCR after BMT are at significantly 
greater risk of relapse. Conversely, those CML 
patients persistently BCR/ABL negative are at a 
low risk of relapse. Molecular detection of Phi- 
positive cells can provide information on early re- 
lapse although patients remain in cytogenetic and 
hematologic remission. RT-PCR detection of Phi 
is also useful in establishing the diagnosis of CML. 
Many investigators have reported the use of 
PCR-based methodologies to monitor Phi-positive 
cell populations after BMT [4--10]. A major obsta- 
cle surrounding the routine use of PCR for detect- 
ing MRD is reproducibility and the potential for 
false positive and false negative assays. To over- 
come these problems, we have developed, and de- 
scribe here, an assay system in which template 
quality, assay components, and assay sensitivity 
are internally controlled. 
M a t e r i a l s  a n d  M e t h o d s  
RNA Preparation 
Total cellular RNA was prepared from peripheral 
blood, peripheral blood buffy coats, or peripheral 
blood mononuclear  cells isolated by Ficol l -  
Hypaque,  or cultured B cells and K562 (Phi- 
positive) cells. Cells were either viably frozen or 
directly added to 4 M of guanidinium isothiocy- 
anate. RNA was prepared from 3-5 million cells as 
previously described with minor modifications 
[I 1]. Electrophoretic separation of sample RNA 
preparat ions  through 2% agarose ethidium- 
bromide-stained gels revealed that isolations were 
not free of DNA; however, the relative amount of 
contaminating DNA was consistent from sample 
to sample. 
Reverse Transcription and PCR 
Figure 1 depicts a schematic representation of the 
BCR/ABL mRNA structure and the position of the 
oligonucleotide primers used for its detection. One 
microgram of total cellular RNA was reverse- 
transcribed for 1 h at 42°C in 50 mM Tris-HC1, pH 
8.3, 50 mM KC1, 8 mM MgCI 2, 10 mM DTT, 0.5 
mM dNTP's, and 2 p.g ABL-RT primer using 30 U 
AMV-RT (Seikagaku America, Rockville, MD, 
USA) in a total volume of 50 txl. PCR was per- 
formed directly on 10 ~1 of this material in 10 mM 
Tris-HC1, pH 8.3, 50 mM KCI, 1.6 mM MgC12, 2 
mM DTT, 0.2 mM dNTP's, and 0.2 ~g of each of 
the primers ABL-1 and BCR-1 using 1 U of Taq 
polymerase in a total reaction volume of 50 txl. 
Thirty-five cycles were performed consisting of 
1.25 min at 94°C and 1.5 min at 72°C in a Perkin- 
Elmer 480 thermalcycler. All PCRs were termi- 
nated after a 10-min extension at 72°C. Second- 
round PCR was performed using the internally 
nested primers (BCR-2 and ABL-2) with 1 Ixl of the 
first-round PCR product as template for an addi- 
tional 35 cycles. The sequences of the oligonucle- 
otide primers BCR-I, BCR-2, ABL-1, ABL-2, and 
ABL-3 have been previously described [2]. A total 
of 15 txl of each amplified PCR product was ana- 
lyzed by electrophoresis through 2% agarose gels 
and stained with ethidium bromide. 
Assay Control 
Specific measures to ensure accurate results in 
routine testing were incorporated into this assay. 
All RNA isolations, cDNA synthesis, and all set- 
ups (except for introduction of second-round PCR 
mRNA M - B C R  e x o n  3 A B L  e x o n  2 3' 
< A B O R T  
B C R - I >  < A B ~ I  
B C R - 2 >  < A B b 2  
Figure 1. Structure of the B3A2 Phl mRNA and locations of primers used for reverse transcription and nested primer PCR. The 
~ d u c t s  generated from a B3A2 Phl are 392 bp and 300 bp, respectively. The PCR products generated from a B2A2 Phl are 
75 bp shorter. 
© 1994 Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010 
92 
GATA 11(4): 90-94, 1994 M.J. Hessner et al. 
template) were performed in a positive pressure 
high-efficiency particulate air (HEPA)-filtered 
clean room to prevent the introduction of previ- 
ously amplified material. The evaluation of RNA 
integrity and adequate cDNA synthesis from sam- 
ples was accomplished through the detection of 
the constitutively expressed ABL mRNA from the 
same reverse transcription reaction. The ABL 
cDNA was amplified using the primers ABL-I and 
ABL-3 (which targets ABL exon la). Assay sensi- 
tivity was monitored through the addition and de- 
tection of 0.05 ng K562 RNA mixed within a rep- 
licate assay for each unknown sample. This RNA 
quantity represents nucleic acid isolated from - 5  
K562 cells, which requires two rounds of nested 
primer PCR for detection. Failure to detect the 
"spiked" K562 RNA could indicate the presence 
of inhibitors or ribonucleases within the unknown 
RNA sample. Mock RNA preparations were in- 
cluded in every assay as negative-control RNA to 
survey the possibility of false positives due to the 
introduction of previously amplified DNA. All 
sample and control RNAs were analyzed in dupli- 
cate, beginning with independent RNA isolations. 
R e s u l t s  a n d  D i s c u s s i o n  
Assay Sensitivity 
Figure 2 shows the sensitivity ofBCR/ABL mRNA 
detection by RT-PCR. Assays were performed us- 
ing RNA isolated from decreasing numbers of 
K562 cells mixed with 10 6 normal cultured cells. 
The K562 cell line possesses the B3A2 Phi. With 
one round of PCR it is possible to detect as few as 
1000 Phi-positive cells admixed with 1 million nor- 
mal cells (Figure 2, lane B2). After the second 
round of PCR, using the internally nested primers, 
it is possible to detect as few as one Phi-positive 
cell admixed with 1 million normal cells (Figure 2, 
lane C3). 
Assay Validation 
A validation study of 82 samples was performed 
using 25 prepared dilutions of K562 cells into nor- 
mal cultured B cells, 26 pre- and posttransplant 
peripheral blood samples from CML patients, 16 
peripheral blood samples for diagnosis of CML, 
and 15 peripheral blood samples from healthy in- 
dividuals. Samples were tested in duplicate, with 
both the ABL positive control and "spiked" K562 
positive control; additionally, negative-control 
samples were included with every assay. The re- 
sults of this study are provided in Table 1. Dilu- 
tions of K562 cells (106, 103, 10, and 1) mixed with 
3 x 10 6 normal cultured B cells were prepared and 
tested in a blind manner. The presence of 10 6 and 
10 3 K562 cells admixed with 3 x 10 6 normal cul- 
tured B cells was detected always in the first and 
second rounds of PCR. Ten K562 cells admixed 
with 3 x 10 6 normal cultured B cells always re- 
quired two rounds of PCR for detection. One K562 
cell admixed with 3 x 106 normal cultured B cells 
was detected after two rounds of PCR 2/5 times. 
The bcr/abl oncogene message was never detected 
in the samples that contained no K562 cells or 
negative controls. 
Samples from 26 pre- and post-BMT patients 
were assayed for Phi by nested primer PCR at the 
Blood Center of Southeastern Wisconsin; these 
samples had also been previously assayed at an 
independent institution under similar but not iden- 
tical conditions. A concordance rate of 85% (22 
A B 
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Figure 2. Sensitivity and specificity of nested primer PCR detection of Phl.  All sample sets are run in the following order: (1) ABL 
~ a m p l i f i c a t i o n ,  (2) BCR/ABL first-round amplification, and (3) BCR/ABL second-round amplification. (Set A) 106 K562 cells 
mixed with l06 normal cultured B cells. (Set B) 1000 K562 cells mixed with l06 normal cultured B cells. (Set C) 1 K562 cell mixed 
with 106 normal cultured B cells. (Set D) 106 normal cultured B cells. 
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Table 1. Results of 82-Sample Validation Study 
Sample set No. of samples % Reproducible ~ % Concordance b 
K562/B-cell dilutions 25 100 100 (25/25) 
Pre- and post-BMT samples 26 100 85 (22/26) 
Clinical samples for diagnosis 16 100 100 (16/16) 
Healthy donor samples 15 100 100 (15/15) 
"Percent of samples internally reproducible when assayed in duplicate. 
bPercent of samples in concordance with independent measurements. 
samples of 26 patients) was seen within this sam- 
ple subset; all four discrepancies (two positive and 
two negative) were in the second round of PCR. 
When these four samples were previously tested, 
RNA template was not quantified; therefore, an 
unknown amount of RNA was surveyed. In assays 
performed at the Blood Center of Southeastern 
Wisconsin, however, RNA isolations were quan- 
tified, with 1 Ixg of starting nucleic acid always 
added into reverse transcription reactions. Al- 
though nucleic acid isolations at both institutions 
were similar, the observed discrepancies in this 
sample subset may have been due to differences in 
the quantity of RNA surveyed. It is also expected 
that some assay variability will exist when sam- 
ples that possess numbers of Phi-positive cells 
near the threshold level of detection are tested. 
This variability is partly controlled by duplicate 
testing of all samples from independent RNA iso- 
lations. 
Sixteen pretreatment / t ransplant  peripheral 
blood samples were provided for analysis by local 
hematologists and oncologists. In all 16 cases, 
there was 100% concordance between the molec- 
ular analysis by nested primer RT-PCR and cyto- 
genetic analysis. In addition, a random selection 
of 15 healthy blood donor samples were assayed 
for the presence of Phi. All samples were negative 
for BCR/ABL and positive for ABL, as expected; 
all K562 positive control samples indicated the 
predicted sensitivity. These results are also sum- 
marized in Table 1. 
Representative analysis of clinical samples is 
shown in Figure 3. Panel A shows the analysis of 
an individual with clinical evidence of CML. The 
presence of a B3A2 BCR/ABL is indicated by the 
392-bp PCR product detected after one round of 
amplification (lane A1). Cytogenetic analysis of 
this patient confirmed the presence of a Phi.  
Lanes A4 through A6 are the ABL, BCR/ABL pri- 
mary, and BCR/ABL secondary amplifications for 
the K562 spiked replicate control set, respec- 
tively. Figure 3B shows the MRD analysis of a 
peripheral blood sample from a CML patient 211 
days after BMT. Residual disease was detected as 
indicated by the presence of a 300-bp band, cor- 
responding to a B3A2 Phi, in the second round of 
PCR (lane B3). Panel C shows the analysis of a 
peripheral blood sample from an individual pre- 
senting with a clinical suspicion of CML. This 
sample was negative for the presence of either a 
B2A2 or B3A3 Phl after two rounds of PCR (lane 
C3). The sample RNA integrity was adequate as 
indicated by the presence of a 250-bp ABL PCR 
A B C 




Figure 3. Nested primer PCR detection of Phl  in patient samples. All sample sets are run in the following order: (1) ABL control 
~ a t i o n ,  (2) BCR/ABL first-round amplification, (3) BCR/ABL second-round amplification, (4) K562 spiked ABL control 
amplification, (5) K562 spiked BCR/ABL first-round control amplification, and (6) K562 spiked BCR/ABL second-round control 
amplification. (Set A) Patient sample analyzed for diagnosis of CML; patient is Ph 1 positive (lanes A2 and A3). (Set B) CML patient 
sample analyzed after BMT for MRD; patient is Phl positive in the second round of amplification (lane B3). (Set C) Patient sample 
analyzed for diagnosis of CML; patient is Phl  negative (lanes A2 and A3). The patient RNA was of good quality (lane C1) and is 
capable of supporting an assay of predicted sensitivity (lane C6). 
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product in lane C 1. This patient RNA sample was 
capable of supporting a sensitive BCR/ABL ampli- 
fication as indicated by the detection of a 300-bp 
B3A2 band in the spiked replicate control reaction 
(lane C6). Cytogenetic analysis of this patient sam- 
ple was negative for Phi but indicated the pres- 
ence of an inversion on the long arm of chromo- 
some 16 (q22q24) associated with acute my- 
elomonocytic leukemia; this is a cytogenetic 
abnormality not associated with CML. 
Conclusions. 
Internally, this assay was 100% reproducible; an 
overall concordance rate of/>95% was observed 
with other measurements (dilution studies, molec- 
ular analysis, cytogenetic analysis). Sensitivity 
was monitored in every assay. Assay components 
(enzymes, primers, buffers) were also internally 
controlled in each assay. Contamination of sam- 
ples was monitored by duplicate sample analysis 
and by the inclusion of blank samples in each as- 
say. This approach provides a very sensitive, re- 
producible, and rapid assay for the presence of 
Phi-positive cells, which has utility not only for 
detection of minimal residual disease after treat- 
ment but as a tool for establishing a diagnosis of 
CML. More important, the steps outlined here for 
assay control can be adaptable to any PCR-based 
detection scheme. 
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